| review article | Q7318358 |
| scholarly article | Q13442814 |
| P2093 | author name string | Denis Horgan | |
| P2860 | cites work | Storylines of research in diffusion of innovation: a meta-narrative approach to systematic review | Q33341163 |
| Why do health technology assessment coverage recommendations for the same drugs differ across settings? Applying a mixed methods framework to systematically compare orphan drug decisions in four European countries | Q33840393 | ||
| IMPROVING THE EFFECTIVENESS AND EFFICIENCY OF EVIDENCE PRODUCTION FOR HEALTH TECHNOLOGY ASSESSMENT. | Q36419661 | ||
| Paying for the Orphan Drug System: break or bend? Is it time for a new evaluation system for payers in Europe to take account of new rare disease treatments? | Q36639084 | ||
| Value-Based Assessment of New Medical Technologies: Towards a Robust Methodological Framework for the Application of Multiple Criteria Decision Analysis in the Context of Health Technology Assessment. | Q36789255 | ||
| Medical devices early assessment methods: systematic literature review | Q38210009 | ||
| Improving the contribution of regulatory assessment reports to health technology assessments--a collaboration between the European Medicines Agency and the European network for Health Technology Assessment | Q38240272 | ||
| Early market access of cancer drugs in the EU. | Q38612833 | ||
| Developing an evidence-based methodological framework to systematically compare HTA coverage decisions: A mixed methods study. | Q38684831 | ||
| Assessing the added value of health technologies: reconciling different perspectives | Q39484580 | ||
| Problems and promises of innovation: why healthcare needs to rethink its love/hate relationship with the new. | Q42706075 | ||
| Biomedical innovation in the era of health care spending constraints | Q46242272 | ||
| Health technology assessment, value-based decision making, and innovation. | Q51188177 | ||
| A history of health technology assessment at the European level. | Q53101034 | ||
| The HTA core model: a novel method for producing and reporting health technology assessments. | Q53181827 | ||
| Approvals of drugs with uncertain benefit-risk profiles in Europe. | Q53360504 | ||
| Another special relationship? Interactions between health technology policies and health care systems in the United States and the United Kingdom | Q57153120 | ||
| Nasty or nice? A perspective on the use of health technology assessment in the United Kingdom | Q84065654 | ||
| Drug Regulation and Pricing--Can Regulators Influence Affordability? | Q89414153 | ||
| Redirecting Innovation in U.S. Health Care: Options to Decrease Spending and Increase Value | Q89915576 | ||
| P433 | issue | Suppl 1 | |
| P304 | page(s) | 202-211 | |
| P577 | publication date | 2017-11-21 | |
| P1476 | title | Treatment Is Worth a Lot - But Just How Much | |
| P478 | volume | 2 |
Search more.